Cerebras Systems Inc. (NASDAQ:CBRS) begins trading today on the Nasdaq at $185 per share, carrying a $56.4 billion fully diluted valuation into its first morning as a public company. That number is not the story. Rather, the story is what investors are paying for versus what the business actually delivers today, and the gap between those two things is wider than the first-day excitement will suggest.

Institutional Demand Signals Sentiment, Not Value

A 20-times oversubscribed book sounds like validation. In reality, it is not. Specifically, it tells you that institutions wanted more shares than were available at a fixed price, which is a function of supply scarcity and AI sector momentum. The most oversubscribed IPOs in history have both soared and collapsed on day one. Put simply, oversubscription measures demand for an allocation, not conviction in a valuation.

Retail investors entering CBRS at the open today are not getting the institutional price. Instead, they are absorbing the premium that institutional crowding created. The question is not whether AI infrastructure is real. It is whether this valuation, on this revenue base, leaves room to generate a return.

The Revenue Base Does Not Match the Price Tag

At $185, CBRS trades at roughly 110 times its 2025 revenue of $510 million. Using the company's own $24.6 billion backlog, with management projecting 15% recognition across 2026 and 2027, annualized forward revenue approaches $1.85 billion. That puts the forward price-to-sales multiple at approximately 30 times. By comparison, NVIDIA Corporation (NASDAQ:NVDA) trades at roughly 20 times forward revenue, with proven profitability, a dominant software ecosystem, and a customer base spanning every major hyperscaler.

Moreover, the GAAP net income of $237.8 million that appears in headlines came almost entirely from a one-time non-cash gain of $363.3 million on a forward contract liability extinguishment tied to G42, per the Cerebras S-1/A filed May 4, 2026. Strip that out and the operating business posted a $145.9 million operating loss. As a result, investors buying CBRS today are paying a growth premium for a business that has not yet demonstrated it can grow profitably.

The OpenAI Deal Is Smaller Than It Looks

The $20 billion OpenAI commitment anchors every bull argument for CBRS. However, the Financial Times reported that Cerebras is handing OpenAI warrants worth up to 10% of the company, approximately $5 billion at the IPO price, or roughly half the gross profit Cerebras stands to earn on the deal. The headline number and the actual economics are materially different.

Beyond the economics, the Master Relationship Agreement ties Cerebras' future hardware roadmap to a single customer's preferences. If OpenAI's compute strategy shifts, Cerebras does not simply lose a customer. It loses the architectural direction of its next product generation. A $56.4 billion valuation should reflect that dependency explicitly. It does not.

86% of Last Year’s Revenue Came From Two UAE Entities

The customer diversification story underwrites this valuation as a forward projection, not a current reality. Mohamed bin Zayed University of Artificial Intelligence accounted for 62% of 2025 revenue, and G42 contributed another 24%, per the Cerebras prospectus. OpenAI and AWS are the backlog, not the revenue base.

This distinction carries direct regulatory risk. The Bureau of Industry and Security reviews semiconductor export rules on a rolling basis. Any tightening targeting UAE-based customers hits Cerebras asymmetrically. Advanced Micro Devices Inc. (NASDAQ:AMD) and NVDA carry UAE exposure as a fraction of a diversified global book. For CBRS, that exposure is the entire business.

NVIDIA’s All-Time High is Not a Rising Tide for CBRS

NVDA hit an all-time high of $227.84 on Wednesday after Jensen Huang joined President Trump's Beijing delegation, with Bank of America and Wells Fargo both raising price targets ahead of the May 20 earnings report. The Nasdaq added 1.2%, but roughly two-thirds of S&P 500 stocks fell. This was a chip-sector rally, not a broad market move.

The problem for CBRS buyers is that Huang's Beijing visit has reignited hopes that NVDA could resume H200 chip sales in China, a market worth $25 billion in annual revenue before export restrictions cut it to zero. If those restrictions ease, NVDA regains a massive revenue stream. Cerebras gains nothing from that outcome. Its customers are UAE-based, not Chinese.

NVDA's rally today strengthens the dominant competitor in the exact inference market CBRS is targeting, while doing nothing for Cerebras' own revenue position. Investors buying CBRS on today's chip-sector enthusiasm are riding a wave that, if it breaks in NVDA's favor on May 20, leaves CBRS holding a higher multiple against a stronger rival simultaneously.

What to Watch: Four Catalysts With Specific Dates

First, watch where CBRS settles by end of day relative to $185. A close above $240 pushes the forward multiple above 40 times, signaling retail momentum, not fundamentals, is driving price discovery.

Second, watch NVDA earnings on May 20, 2026. Any guidance on China re-entry or inference demand growth directly sets the ceiling on how long CBRS can sustain its current multiple.

Third, watch Cerebras' first quarterly earnings in August 2026. The key number is not revenue growth. It is whether OpenAI and AWS combined exceed 40% of quarterly revenue. Below that threshold, the diversification narrative collapses.

Fourth, watch the share unlock schedule beginning August 2026. The Class B share conversion does not arrive in one single event. Instead, approximately 84 million shares become eligible for sale by August 19. The full 171.1 million shares unlocked by end of October 2026, per MSN's reporting on the S-1 structure. That rolling supply overhang arrives just before Q3 earnings. It will ultimately reveal whether insiders believe this valuation holds, or whether they use it as an exit.

The technology is real. The demand was real. The price, however, was set by an oversubscribed book in a hot sector, not by the numbers inside the prospectus. Those two things tend to converge eventually.

Benzinga Disclaimer: This article is from an unpaid external contributor. It does not represent Benzinga’s reporting and has not been edited for content or accuracy.